Sugi Predict

Sugi Predict / Compounds / SCHEMBL2744735

SCHEMBL2744735

SCHEMBL2744735

COc1cc2ncnc(Oc3ccc(N)cc3F)c2cc1OCCCN1CCOCC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 3/20 0.78
▸ KDR P35968 10/20 0.60
▸ SRC P12931 7/20 0.60
▸ EGFR P00533 6/20 0.60
▸ MET P08581 4/20 0.60
▸ FLT4 P35916 4/20 0.60
▸ RET P07949 3/20 0.60
▸ KIT P10721 3/20 0.60
▸ GAK O14976 2/20 0.60
▸ EPHB6 O15197 2/20 0.60
▸ RIPK2 O43353 2/20 0.60
▸ STK10 O94804 2/20 0.60
▸ MAP4K4 O95819 2/20 0.60
▸ CHEK2 O96017 2/20 0.60
▸ ABL1 P00519 2/20 0.60
▸ ERBB2 P04626 2/20 0.60
▸ LCK P06239 2/20 0.60
▸ LYN P07948 2/20 0.60
▸ HCK P08631 2/20 0.60
▸ FGR P09769 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30001610 1.00 AXL (0.78) AXLKDRSRCEGFRMET
SCHEMBL15084619 1.00 AXL (0.78) AXLKDRSRCEGFRMET
SCHEMBL5570163 0.97 AXL (0.73) AXLKDRSRCEGFRMET
SCHEMBL29631712 0.96 AXL (0.71) AXLKDRSRCEGFRMET
SCHEMBL15084626 0.96 AXL (0.71) AXLKDRSRCEGFRMET
SCHEMBL15084560 0.92 KDR (0.66) AXLKDRSRCEGFRMET
SCHEMBL15084515 0.92 KDR (0.66) AXLKDRSRCEGFRMET
SCHEMBL15084599 0.91 ABCB11 (0.67) AXLKDRSRCEGFRMET
SCHEMBL15084518 0.91 KDR (0.67) AXLKDRSRCEGFRMET
SCHEMBL24444618 0.88 KDR (0.63) AXLKDRSRCEGFRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 — — US disclosed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 — — US disclosed
EP-2392565-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2014-03-19 — — EP disclosed
EP-2213661-A1 c-Met Modulators and Methods of Use Exelixis Inc. (US) 2010-08-04 — — EP disclosed
EP-2210607-A1 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer Exelixis Inc. (US) 2010-07-28 — — EP disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 — — US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
EP-1673085-A4 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2008-12-10 — — EP disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885KDR 4/4885SRC 82/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AXL 109/4885KDR 4/4885SRC 82/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885KDR 5/4885SRC 114/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885KDR 4/4885SRC 82/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET AXL 109/4885KDR 4/4885SRC 82/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 AXL 239/4885KDR 5/4885SRC 101/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 AXL 241/4885KDR 5/4885SRC 114/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885KDR 5/4885SRC 114/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET AXL 109/4885KDR 4/4885SRC 82/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 AXL 239/4885KDR 5/4885SRC 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.